HomeMOLN • NASDAQ
add
Molecular Partners AG
Previous close
$4.71
Day range
$4.10 - $4.63
Year range
$3.36 - $5.36
Market cap
173.55M USD
Avg Volume
2.87K
P/E ratio
-
Dividend yield
-
In the news
Financials
Income Statement
Revenue
Net income
| (CHF) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 43.62M | 716.09% |
Net income | -12.65M | -12.62% |
Net profit margin | — | — |
Earnings per share | -0.36 | -20.00% |
EBITDA | -12.15M | 16.45% |
Effective tax rate | -0.03% | — |
Balance Sheet
Total assets
Total liabilities
| (CHF) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 93.06M | -37.73% |
Total assets | 102.11M | -35.59% |
Total liabilities | 21.77M | 28.90% |
Total equity | 80.33M | — |
Shares outstanding | 37.79M | — |
Price to book | 2.21 | — |
Return on assets | -29.56% | — |
Return on capital | -34.98% | — |
Cash Flow
Net change in cash
| (CHF) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -12.65M | -12.62% |
Cash from operations | -11.15M | 15.49% |
Cash from investing | 11.95M | 365.95% |
Cash from financing | -300.00K | -101.96% |
Net change in cash | 294.00K | 115.65% |
Free cash flow | -15.02M | -136.94% |
About
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Founded
2004
Website
Employees
153
